Mydecine Innovations Group Inc. announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been specifically designed by experts at Mydecine to have a shorter half life than traditional MDMA. The Company has named this family of novel molecules MYCO-006 and have applied for patent coverage with the World Intellectual Property Organization.

3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a synthetic drug that acts as a stimulant and hallucinogen. In July 2021, Mydecine announced [2]a provisional patent application for a familyof MDMA-like compounds intended to reduce harm and improve safety compared to the traditional drug. Mydecine is targeting a 1-2 hour duration novel MDMA analog that will produce the same effects as traditional MDMA.

Current recommended treatments [5] for PTSD include trauma-focused psychotherapies, such as prolonged exposure, cognitive processing therapy, and eye movement desensitization and reprocessing. MDMA has been shown toincrease feelings of well-being and interpersonal trust while decreasing feelings of fear and defensiveness. For these reasons, research has shown MDMA can increase the effectiveness of therapy.